Drug Profile
Research programme: type-2 diabetes mellutis therapeutic - Xeragenx/Syracuse University
Latest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator Syracuse University; Xeragenx Plant Sciences
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Jan 2020 No recent reports of development identified for research development in Type-2-diabetes-mellitus in USA (PO)
- 10 Dec 2015 Early research in Type-2 diabetes mellitus in USA (PO)